Vimizim (Elosulfase Alfa)

 Vimizim (elosulfase alfa) is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme used for the treatment of patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

Recommended Dosage: The recommended dose of Vimizim is 2 mg per kg administered intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. Pre-treatment with antihistamines with or without antipyretics is recommended 30 to 60 minutes prior to the start of the infusion.

• Vimizim 5 mg/5 mL can cause severe allergic reactions, including anaphylaxis. Monitor patients closely during and after the infusion. If anaphylaxis or severe allergic reactions occur, promptly discontinue Vimizim and initiate appropriate medical treatment.
• Infusion-related reactions, such as headache, nausea, fever, and chills, may occur. Pre-medicate with antihistamines and/or antipyretics to minimize these reactions. Monitor patients during infusions and manage reactions as needed.
• Patients with a history of sleep apnea or upper airway obstruction should be monitored carefully. Evaluate airway patency before initiation of treatment, especially in pediatric patients.
• Monitor patients for signs and symptoms of spinal or cervical cord compression, such as back pain, limb weakness, and bladder or bowel dysfunction. If symptoms occur, provide appropriate medical intervention.
• The safety of Elosulfase Alfa 5 mg/5 mL during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus. Monitor pregnant women closely for hypersensitivity reactions.
• It is not known whether Vimizim is excreted in human milk. Caution should be exercised when administered to breastfeeding women. Consider the benefits of breastfeeding along with the mother’s clinical need for Vimizim and any potential adverse effects on the breastfed child.

What documents are required to import VIMIZIM to India?

VIMIZIM (elosulfase alfa) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is VIMIZIM available in India?

VIMIZIM (elosulfase alfa injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Vimizim in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

VIMIZIM can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of VIMIZIM (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Vimizim 5 mg/5 mL price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.